SCHEMBL1122499

SCHEMBL1122499

CC(=O)c1ccc(Oc2cncc(Cl)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.53
MAPT P10636 1/20 0.53
HPGD P15428 1/20 0.53
BRAF P15056 2/20 0.52
SMN1; SMN2 Q16637 4/20 0.43
GAA P10253 2/20 0.43
TSHR P16473 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NTRK1 P04629 1/20 0.43
KMT2A Q03164 1/20 0.43
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
GLA P06280 1/20 0.41
BCHE P06276 2/20 0.40
ACHE P22303 2/20 0.40
ICAM1 P05362 1/20 0.40
SELE P16581 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17077631 0.83 RAB9A (0.55) RAB9AMAPTHPGDBRAFSMN1; SMN2
SCHEMBL1122184 0.83 BRAF (0.56) BRAFNPSR1NTRK1KMT2AALDH1A1
SCHEMBL1122188 0.81 KMT2A (0.63) HPGDBRAFSMN1; SMN2NTRK1KMT2A
SCHEMBL17354820 0.79 MEN1 (0.50) RAB9AMAPTHPGDGAATSHR
SCHEMBL11374043 0.79 HTT (0.50) RAB9AMAPTBRAFNPSR1NTRK1
SCHEMBL11375970 0.79 HTT (0.53) NTRK1KMT2APPARGPPARAL3MBTL1
SCHEMBL18355733 0.76 KMT2A (0.68) RAB9AMAPTHPGDBRAFSMN1; SMN2
SCHEMBL11822252 0.76 TSHR (0.51) MAPTBRAFSMN1; SMN2TSHRNTRK1
SCHEMBL11373513 0.76 HTT (0.47) RAB9AHPGDBRAFTSHRNPSR1
SCHEMBL15149228 0.76 MEN1 (0.50) MAPTGAANTRK1KMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831184-B1 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS WELLCOME TRUST LTD (GB) 2011-02-09 EP disclosed
EP-1831184-B1 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS WELLCOME TRUST LTD (GB) 2011-02-09 EP disclosed
US-7737152-B2 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compounds THE WELLCOME TRUST LIMITED (GB) 2010-06-15 US disclosed
US-20080015191-A1 Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds THE WELLCOME TRUST LIMITED (UK) 2008-01-17 US disclosed
US-20080015191-A1 Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds THE WELLCOME TRUST LIMITED (UK) 2008-01-17 US disclosed
US-20080015191-A1 Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds THE WELLCOME TRUST LIMITED (UK) 2008-01-17 US disclosed
EP-1831184-A2 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS The Wellcome Trust Limited (GB) 2007-09-12 EP disclosed
WO-2006067466-A2 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS THE WELLCOME TRUST LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015191-A1 Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds BRAF, RAF1, BCOR RAB9A 1909/4885MAPT 4774/4885HPGD 2517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.